Publications 2022

Schmitz A, Brøndum RF, Johnsen HE, Mellqvist UH, Waage A, Gimsing P, Op Bruinink DH, van der Velden V, van der Holt B, Hansson M, Andersen NF, Frølund UC, Helleberg C, Schjesvold FH, Ahlberg L, Gulbrandsen N, Andreasson B, Lauri B, Haukas E, Bødker JS, Roug AS, Bøgsted M, Severinsen MT, Gregersen H, Abildgaard N et al. (2022)
Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission - results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial
BMC Cancer, 22 (1), 147
DOI 10.1186/s12885-022-09184-1, PubMed 35123422

Publications 2021

Gregersen H, Peceliunas V, Remes K, Schjesvold F, Abildgaard N, Nahi H, Andersen NF, Vangsted AJ, Klausen TW, Helleberg C, Carlson K, Frølund UC, Axelsson P, Stromberg O, Blimark CH, Crafoord J, Tsykunova G, Eshoj HR, Waage A, Hansson M, Gulbrandsen N (2021)
Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma: A randomised phase 2 trial by the Nordic Myeloma Study Group
Eur J Haematol, 108 (1), 34-44
DOI 10.1111/ejh.13709, PubMed 34536308

Kaiser M, Beksaç M, Gulbrandsen N, Schjesvold F, Hájek R, Moreau P, de la Fuente FA, Mateos MV, West S, Spencer A, Rajkumar SV, Suryanarayan K, Czorniak M, Li C, Teng Z, Labotka R, Dimopoulos MA (2021)
Correction to: Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma
Ann Hematol, 100 (1), 297-302
DOI 10.1007/s00277-020-04302-0, PubMed 33106909

Sonneveld P, Dimopoulos MA, Beksac M, van der Holt B, Aquino S, Ludwig H, Zweegman S, Zander T, Zamagni E, Wester R, Hajek R, Pantani L, Dozza L, Gay F, Cafro A, De Rosa L, Morelli A, Gregersen H, Gulbrandsen N, Cornelisse P, Troia R, Oliva S, van de Velden V, Wu K, Ypma PF et al. (2021)
Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma
J Clin Oncol, 39 (32), 3613-3622
DOI 10.1200/JCO.21.01045, PubMed 34520219

Tjonnfjord GE, Schjesvold FH, Gulbrandsen N, Kvam AK (2021)
Monoclonal gammopathy of clinical importance
Tidsskr. Nor. Laegeforen., 141 (13), 1276-1280

Tjønnfjord GE, Schjesvold FH, Gulbrandsen N, Kvam AK (2021)
[Monoclonal gammopathy of clinical importance]
Tidsskr Nor Laegeforen, 141 (2021-13)
DOI 10.4045/tidsskr.20.0981, PubMed 34596996

Publications 2020

Kaiser M, Beksaç M, Gulbrandsen N, Schjesvold F, Hájek R, Moreau P, de Arriba de la Fuente F, Mateos MV, West S, Spencer A, Rajkumar SV, Suryanarayan K, Czorniak M, Li C, Teng Z, Labotka R, Dimopoulos MA (2020)
Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma
Ann Hematol, 99 (8), 1793-1804
DOI 10.1007/s00277-020-04149-5, PubMed 32613281

Publications 2018

Tangen JM, Tjønnfjord GE, Gulbrandsen N, Gedde-Dahl T, Stormorken E, Anderson K, Vo CD, Schjesvold FH, For Oslo Myeloma Center (2018)
Improved outcome in patients following autologous stem cell transplantation for multiple myeloma in south eastern Norway 2001-2010: a retrospective, population based analysis
BMC Cancer, 18 (1), 801
DOI 10.1186/s12885-018-4722-x, PubMed 30089450

Publications 2013

Mellqvist UH, Gimsing P, Hjertner O, Lenhoff S, Laane E, Remes K, Steingrimsdottir H, Abildgaard N, Ahlberg L, Blimark C, Dahl IM, Forsberg K, Gedde-Dahl T, Gregersen H, Gruber A, Guldbrandsen N, Haukås E, Carlson K, Kvam AK, Nahi H, Lindås R, Andersen NF, Turesson I, Waage A, Westin J et al. (2013)
Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial
Blood, 121 (23), 4647-54
DOI 10.1182/blood-2012-11-464503, PubMed 23616624

Publications 2012

Hjorth M, Hjertner Ø, Knudsen LM, Gulbrandsen N, Holmberg E, Pedersen PT, Andersen NF, Andréasson B, Billström R, Carlson K, Carlsson MS, Flogegård M, Forsberg K, Gimsing P, Karlsson T, Linder O, Nahi H, Othzén A, Swedin A, Nordic Myeloma Study Group (NMSG) (2012)
Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study
Eur J Haematol, 88 (6), 485-96
DOI 10.1111/j.1600-0609.2012.01775.x, PubMed 22404182

Publications 2011

Nilsson-Ehle H, Birgegård G, Samuelsson J, Antunovic P, Astermark J, Garelius H, Engström LM, Kjeldsen L, Nilsson L, Olsson A, Skov-Holm M, Wallvik J, Gulbrandsen N, Hellström-Lindberg E (2011)
Quality of life, physical function and MRI T2* in elderly low-risk MDS patients treated to a haemoglobin level of ≥120 g/L with darbepoetin alfa ± filgrastim or erythrocyte transfusions
Eur J Haematol, 87 (3), 244-52
DOI 10.1111/j.1600-0609.2011.01654.x, PubMed 21623919

Publications 2010

Waage A, Gimsing P, Fayers P, Abildgaard N, Ahlberg L, Björkstrand B, Carlson K, Dahl IM, Forsberg K, Gulbrandsen N, Haukås E, Hjertner O, Hjorth M, Karlsson T, Knudsen LM, Nielsen JL, Linder O, Mellqvist UH, Nesthus I, Rolke J, Strandberg M, Sørbø JH, Wisløff F, Juliusson G, Turesson I et al. (2010)
Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma
Blood, 116 (9), 1405-12
DOI 10.1182/blood-2009-08-237974, PubMed 20448107

Publications 2009

Bird J, Behrens J, Westin J, Turesson I, Drayson M, Beetham R, D'Sa S, Soutar R, Waage A, Gulbrandsen N, Gregersen H, Low E, Haemato-oncology Task Force of the British Committee for Standards in Haematology, UK Myeloma Forum and Nordic Myeloma Study Group (2009)
UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS)
Br J Haematol, 147 (1), 22-42
DOI 10.1111/j.1365-2141.2009.07807.x, PubMed 19673884

Iversen PO, Wisløff F, Gulbrandsen N (2009)
Reduced nutritional status among multiple myeloma patients during treatment with high-dose chemotherapy and autologous stem cell support
Clin Nutr, 29 (4), 488-91
DOI 10.1016/j.clnu.2009.12.002, PubMed 20044183

Kvam AK, Fayers P, Hjermstad M, Gulbrandsen N, Wisloff F (2009)
Health-related quality of life assessment in randomised controlled trials in multiple myeloma: a critical review of methodology and impact on treatment recommendations
Eur J Haematol, 83 (4), 279-89
DOI 10.1111/j.1600-0609.2009.01303.x, PubMed 19558508

Publications 2008

Iversen PO, Ukrainchenko E, Afanasyev B, Hulbekkmo K, Choukah A, Gulbrandsen N, Wisløff F, Tangen JM (2008)
Impaired nutritional status during intensive chemotherapy in Russian and Norwegian cohorts with acute myeloid leukemia
Leuk Lymphoma, 49 (10), 1916-24
DOI 10.1080/10428190802339723, PubMed 18949615

Piehler AP, Gulbrandsen N, Kierulf P, Urdal P (2008)
Quantitation of serum free light chains in combination with protein electrophoresis and clinical information for diagnosing multiple myeloma in a general hospital population
Clin Chem, 54 (11), 1823-30
DOI 10.1373/clinchem.2008.106153, PubMed 18801937

Publications 2006

Gulbrandsen N (2006)
Health related quality of life and cost-utility in the treatment of multiple myeloma
In Series of dissertations submitted to the Faculty of Medicine, University of Oslo, Unipub, Oslo, no. 437, 1 b. (flere pag.)
BIBSYS 061837156

Publications 2005

Wisløff F, Gulbrandsen N, Hjorth M, Lenhoff S, Fayers P (2005)
Quality of life may be affected more by disease parameters and response to therapy than by haemoglobin changes
Eur J Haematol, 75 (4), 293-8
DOI 10.1111/j.1600-0609.2005.00509.x, PubMed 16146535

Publications 2004

Gulbrandsen N, Hjermstad MJ, Wisløff F, Nordic Myeloma Study Group (2004)
Interpretation of quality of life scores in multiple myeloma by comparison with a reference population and assessment of the clinical importance of score differences
Eur J Haematol, 72 (3), 172-80
DOI 10.1046/j.0902-4441.2003.00195.x, PubMed 14962235

Waage A, Gimsing P, Juliusson G, Turesson I, Gulbrandsen N, Eriksson T, Hjorth M, Nielsen JL, Lenhoff S, Westin J, Wislöff F, Nordic Myeloma Study Group (2004)
Early response predicts thalidomide efficiency in patients with advanced multiple myeloma
Br J Haematol, 125 (2), 149-55
DOI 10.1111/j.1365-2141.2004.04879.x, PubMed 15059136

Publications 2003

Hellström-Lindberg E, Gulbrandsen N, Lindberg G, Ahlgren T, Dahl IM, Dybedal I, Grimfors G, Hesse-Sundin E, Hjorth M, Kanter-Lewensohn L, Linder O, Luthman M, Löfvenberg E, Oberg G, Porwit-MacDonald A, Rådlund A, Samuelsson J, Tangen JM, Winquist I, Wisloff F, Scandinavian MDS Group (2003)
A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life
Br J Haematol, 120 (6), 1037-46
DOI 10.1046/j.1365-2141.2003.04153.x, PubMed 12648074